Nabriva Therapeutics Ag Stock Current Liabilities
| NBRVDelisted Stock | USD 1.62 0.01 0.61% |
Nabriva Therapeutics AG fundamentals help investors to digest information that contributes to Nabriva Therapeutics' financial success or failures. It also enables traders to predict the movement of Nabriva Stock. The fundamental analysis module provides a way to measure Nabriva Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nabriva Therapeutics stock.
Nabriva |
Nabriva Therapeutics AG Company Current Liabilities Analysis
Nabriva Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Nabriva Therapeutics Current Liabilities | 14 M |
Most of Nabriva Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nabriva Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Nabriva Therapeutics AG has a Current Liabilities of 14 M. This is 99.2% lower than that of the Pharmaceuticals sector and 97.42% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.82% higher than that of the company.
Nabriva Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nabriva Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nabriva Therapeutics could also be used in its relative valuation, which is a method of valuing Nabriva Therapeutics by comparing valuation metrics of similar companies.Nabriva Therapeutics is currently under evaluation in current liabilities category among its peers.
Nabriva Fundamentals
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 8.77 % | |||
| Number Of Shares Shorted | 44.59 K | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 0.24 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 35.67 M | |||
| Gross Profit | (10.23 M) | |||
| EBITDA | (54.7 M) | |||
| Net Income | (57.19 M) | |||
| Cash And Equivalents | 20.04 M | |||
| Cash Per Share | 7.53 X | |||
| Total Debt | 5.22 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 2.81 X | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (36.71 M) | |||
| Short Ratio | 8.58 X | |||
| Earnings Per Share | (19.67) X | |||
| Price To Earnings To Growth | (0.06) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 39 | |||
| Beta | 1.56 | |||
| Market Capitalization | 4.55 M | |||
| Total Asset | 31.77 M | |||
| Retained Earnings | (652.86 M) | |||
| Working Capital | 3.5 M | |||
| Current Asset | 83 M | |||
| Current Liabilities | 14 M | |||
| Z Score | -32.68 | |||
| Net Asset | 31.77 M |
About Nabriva Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nabriva Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nabriva Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nabriva Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |